UBA7 Antibody

What is UBA7 and why is it important in cellular research?

UBA7 (Ubiquitin Like Modifier Activating Enzyme 7), also known as UBE1L, is a critical member of the E1 ubiquitin-activating enzyme family involved in post-translational protein modification . It catalyzes the first step in the ISGylation pathway by activating ISG15, a ubiquitin-like protein that modifies substrate proteins post-translationally . UBA7's importance lies in its role in protein degradation pathways and its potential tumor suppressor functions. It triggers promyelocytic leukemia (PML)/retinoic acid receptor alpha (RARalpha) degradation and apoptosis in acute promyelocytic leukemia . Understanding UBA7 function has significant implications for cancer research, particularly in studying interferon-regulated cellular processes and tumor suppression mechanisms.

What types of UBA7 antibodies are available for research applications?

Several types of UBA7 antibodies are available for research applications, each optimized for specific experimental techniques:

• Polyclonal antibodies: These recognize multiple epitopes on the UBA7 protein, such as rabbit polyclonal antibodies that target the N-terminal region of human UBA7 (amino acids 239-268) .

• Monoclonal antibodies: These recognize specific epitopes with high specificity and are available for applications requiring consistent results across experiments .

The available antibodies vary in host species (primarily rabbit), reactivity (primarily human), and applications:

When selecting an antibody, researchers should consider the specific experimental application, species reactivity requirements, and validation data available for each product .

What are the optimal conditions for using UBA7 antibodies in Western blotting?

For optimal Western blotting with UBA7 antibodies, consider the following methodological approach:

• Sample preparation: UBA7 has a calculated molecular weight of approximately 112 kDa . Use appropriate lysis buffers that preserve protein integrity and phosphorylation status if studying post-translational modifications.

• Gel selection: Use 8-10% SDS-PAGE gels to achieve good separation of this higher molecular weight protein.

• Transfer conditions: Use wet transfer with 20% methanol for proteins of this size, transferring at lower voltage for longer duration (30V overnight or 100V for 2 hours).

• Blocking and antibody dilution:

  • Block membranes in 5% non-fat dry milk or BSA in TBST

  • Use the recommended antibody dilution of 1:1000 for Western blotting applications

  • Incubate primary antibody overnight at 4°C for optimal signal-to-noise ratio

• Detection system: Both chemiluminescence and fluorescence-based detection systems are compatible. Select based on your laboratory's equipment and sensitivity requirements.

• Controls: Include positive controls (cell lines known to express UBA7) and negative controls (UBA7-deficient samples or siRNA knockdown samples) to validate specificity.

How should UBA7 antibodies be utilized in immunohistochemistry applications?

For immunohistochemistry applications with UBA7 antibodies, follow these methodological guidelines:

• Tissue preparation: UBA7 antibodies have been validated for use in paraffin-embedded tissues (IHC-P). Optimal fixation is typically achieved with 10% neutral buffered formalin for 24-48 hours.

• Antigen retrieval: Heat-mediated antigen retrieval using citrate buffer (pH 6.0) is recommended for optimal epitope exposure.

• Antibody dilution and incubation:

  • For IHC-P applications, use dilutions between 1:10 to 1:50

  • Incubate sections with primary antibody for 1 hour at room temperature or overnight at 4°C

  • For visualization, use appropriate secondary antibodies such as Alexa Fluor 488 goat anti-rabbit IgG at 1:400 dilution

• Counterstaining: DAPI counterstaining for 5 minutes is effective for nuclear visualization .

• Controls: Include appropriate controls, including secondary antibody-only controls to detect non-specific binding . Tissues from UBA7-knockout models can serve as excellent negative controls.

• Optimization: Always optimize the antibody concentration for your specific tissue type and fixation conditions, as the recommended dilutions are starting points.

What are common challenges when working with UBA7 antibodies and how can they be addressed?

Researchers frequently encounter several challenges when working with UBA7 antibodies:

• High background signal:

  • Problem: Non-specific binding leading to high background noise

  • Solution: Increase blocking time (2-3 hours), use alternative blocking agents (5% BSA instead of milk), increase washing steps duration, and optimize antibody dilution. For Western blots, consider reducing the amount of total protein loaded.

• Weak or absent signal:

  • Problem: Insufficient detection of UBA7 protein

  • Solution: Verify UBA7 expression in your samples through RT-PCR, increase protein loading, extend primary antibody incubation time, ensure proper antigen retrieval for IHC, and test multiple antibodies targeting different epitopes.

• Multiple bands in Western blot:

  • Problem: Detection of non-specific proteins or isoforms

  • Solution: Use more stringent washing conditions, optimize antibody concentration, and validate with positive/negative controls. Consider that UBA7 may undergo post-translational modifications resulting in multiple bands.

• Poor reproducibility:

  • Problem: Inconsistent results between experiments

  • Solution: Standardize protocols meticulously, aliquot antibodies to avoid freeze-thaw cycles, and store at -20°C as recommended . Prepare fresh working solutions for each experiment.

• Cross-reactivity issues:

  • Problem: Antibody binding to non-target proteins

  • Solution: Verify antibody specificity through knockout/knockdown validation, use antibodies with extensive validation data (4-5 validations reported) , and consider pre-adsorption with recombinant proteins for highly sensitive applications.

How can researchers validate UBA7 antibody specificity for their particular experimental model?

Proper validation of UBA7 antibodies is critical for experimental rigor and reproducibility. A systematic validation approach includes:

• Genetic validation:

  • Use UBA7/UBE1L knockout or knockdown models as negative controls

  • Compare expression in wild-type vs. UBA7-deficient samples (as demonstrated in the K-ras LA2 mice model studies)

• Peptide competition assay:

  • Pre-incubate the antibody with the immunizing peptide (such as the synthetic peptide from amino acids 239-268 of human UBA7)

  • A significant reduction in signal indicates specificity for the target epitope

• Multiple antibody approach:

  • Use antibodies from different sources or those recognizing different epitopes

  • Consistent detection pattern across antibodies increases confidence in specificity

• Molecular weight verification:

  • Confirm detection at the expected molecular weight (calculated MW: 112 kDa)

  • Address any unexpected bands through literature review and experimental validation

• Correlation with mRNA expression:

  • Compare protein detection with mRNA expression patterns

  • Concordance between protein and mRNA supports antibody validity

• Application-specific controls:

  • For IHC/IF: Include isotype controls and secondary-only controls

  • For IP: Perform reverse immunoprecipitation and mass spectrometry validation

How can UBA7 antibodies be utilized to investigate the ISGylation pathway in cancer models?

UBA7 antibodies provide valuable tools for investigating the ISGylation pathway in cancer research contexts:

Advanced methodological approaches might include combining UBA7 antibody detection with proximity ligation assays to visualize protein interactions in situ or utilizing chromatin immunoprecipitation (ChIP) to investigate regulatory mechanisms if UBA7 has nuclear functions.

What are the considerations for using UBA7 antibodies in multiplex immunofluorescence protocols?

Multiplex immunofluorescence offers powerful insights into protein co-localization and cellular context. When incorporating UBA7 antibodies into multiplex protocols, researchers should consider:

• Antibody compatibility:

  • Ensure all primary antibodies in the multiplex panel are raised in different host species or use directly conjugated primary antibodies

  • UBA7 rabbit antibodies can be paired with mouse, rat, or goat antibodies targeting other proteins

• Signal optimization:

  • Balance signal strength across all targets by adjusting antibody concentrations

  • Consider the cellular abundance of UBA7 (relatively low in many tissues) when designing detection systems

  • Perform spectral unmixing if fluorophores have overlapping emission profiles

• Sequential staining approach:

  • For complex panels, implement tyramide signal amplification (TSA) with sequential antibody stripping

  • This allows use of multiple rabbit antibodies, including UBA7 antibodies, in the same panel

• Validation controls:

  • Include single-stain controls for each antibody to confirm specificity in the multiplex context

  • Use FFPE cell pellets with known UBA7 expression levels as technical controls on each slide

• Image acquisition and analysis:

  • Capture images at optimal resolution to detect subcellular localization of UBA7

  • Implement computational analysis methods to quantify co-localization with other proteins of interest

  • Consider machine learning approaches for pattern recognition in complex tissues

A recommended protocol might include UBA7 detection with Alexa Fluor 488 (green), paired with ISG15 detection using Alexa Fluor 594 (red) and nuclear counterstaining with DAPI (blue), similar to methods described in previous research .

How should researchers interpret UBA7 expression patterns in relation to ISGylation activity?

Interpreting UBA7 expression patterns requires careful consideration of the relationship between UBA7 protein levels and ISGylation pathway activity:

• Expression-activity correlation analysis:

  • UBA7 protein expression alone may not directly correlate with ISGylation activity

  • Researchers should assess both UBA7 levels and ISG15-conjugated proteins (using anti-ISG15 antibodies) to determine pathway activity

  • The presence of UBA7 is necessary but not sufficient for ISGylation, as downstream E2 and E3 enzymes also regulate the process

• Interferon response dynamics:

  • UBA7 expression is typically interferon-inducible

  • Time-course experiments following interferon treatment can reveal the kinetics of UBA7 upregulation and subsequent ISGylation

  • Discrepancies between UBA7 expression and ISGylation activity may indicate pathway regulation at other levels

• Tissue-specific patterns:

  • UBA7 expression patterns vary across tissue types

  • Comparison with normal adjacent tissue is essential when analyzing tumor samples

  • Heterogeneous expression within tumors may indicate clonal evolution or microenvironmental influences

• Quantification approaches:

  • Use digital image analysis with appropriate software for quantitative assessment

  • For Western blots, normalize UBA7 signal to appropriate housekeeping proteins

  • For IHC, consider H-score or Allred scoring systems for semi-quantitative assessment

• Integration with functional data:

  • Protein ISGylation levels have been observed to remain largely unchanged during lung cancer progression in some models

  • This suggests complex regulation that requires correlation of UBA7 expression with functional outcomes

What considerations should be made when analyzing discrepancies between UBA7 protein detection and gene expression data?

Researchers frequently encounter discrepancies between protein and mRNA expression levels. When analyzing such discrepancies for UBA7, consider:

• Post-transcriptional regulation:

  • miRNAs may regulate UBA7 mRNA stability or translation efficiency

  • RNA-binding proteins might affect translation of UBA7 transcripts

  • Systematic analysis of potential regulatory factors may explain discrepancies

• Protein stability and turnover:

  • UBA7 protein half-life may vary across cell types or disease states

  • Proteasomal degradation pathways might be differentially active

  • Pulse-chase experiments can determine if differences stem from altered protein stability

• Technical considerations:

  • Antibody sensitivity and specificity limitations may affect protein detection

  • RNA-seq or qPCR primer design may capture different transcript variants

  • Standardization of both protein and RNA quantification methods is essential

• Spatial and temporal dynamics:

  • Single-cell analyses might reveal subpopulations with different expression patterns

  • UBA7 expression may fluctuate in response to cellular stresses or cell cycle stage

  • Time-course experiments can capture dynamic changes missed in endpoint analyses

• Integrated analysis approach:

  • Combine multiple methods (Western blot, IHC, qPCR, RNA-seq)

  • Perform correlation analyses with appropriate statistical methods

  • Consider pathway-level analysis rather than focusing solely on UBA7

Understanding these potential sources of discrepancy is crucial when interpreting conflicting results, particularly in the context of UBA7's potential tumor suppressor role, which has shown inconsistent results across different experimental models .

How can UBA7 antibodies be utilized to investigate potential therapeutic targeting of the ISGylation pathway?

The ISGylation pathway represents a promising therapeutic target, particularly in cancer and viral infections. UBA7 antibodies enable several methodological approaches for investigating therapeutic interventions:

• Target engagement studies:

  • UBA7 antibodies can verify binding of small molecule modulators to UBA7 protein

  • Cellular thermal shift assays (CETSA) combined with UBA7 antibody detection can confirm drug-target interactions in intact cells

  • Competitive binding assays can identify compounds that disrupt UBA7-ISG15 interactions

• Pharmacodynamic biomarker development:

  • Monitoring UBA7 protein levels and downstream ISGylation can serve as pharmacodynamic biomarkers

  • IHC or IF with UBA7 antibodies on patient-derived xenografts or clinical samples can assess response to therapy

  • Quantitative image analysis methods should be standardized for reliable biomarker assessment

• Combination therapy evaluation:

  • Since UBA7 is linked to retinoic acid-induced PML/RARα degradation in acute promyelocytic leukemia , antibodies can monitor pathway activation in combination therapies

  • Assessment of synergistic effects between ISGylation modulators and conventional therapies requires reliable quantification of pathway components

• Patient stratification strategies:

  • UBA7 expression patterns detected by validated antibodies might identify patient subgroups likely to respond to specific therapies

  • Development of companion diagnostic approaches using standardized IHC protocols with UBA7 antibodies

• Resistance mechanism investigation:

  • Acquired resistance to therapies targeting ISGylation may involve alterations in UBA7 expression or activity

  • Longitudinal sampling and analysis with UBA7 antibodies can track these changes

What considerations should be made when using UBA7 antibodies in high-throughput screening approaches?

High-throughput screening (HTS) approaches incorporating UBA7 antibodies require specific methodological considerations:

• Assay miniaturization and automation:

  • Adapt traditional Western blot or ELISA protocols to microplate formats

  • Optimize antibody concentration to minimize consumption while maintaining signal-to-noise ratio

  • Implement robotic liquid handling to ensure consistency across large sample sets

• Detection method selection:

  • Choose detection methods amenable to HTS:

    • Fluorescent secondary antibodies offer better quantitative range than HRP-based detection

    • In-cell Western or cytoblot approaches allow direct detection in cultured cells

    • AlphaLISA or similar homogeneous assay formats reduce washing steps

• Quality control measures:

  • Include positive and negative controls on each plate

  • Calculate Z' factor to assess assay robustness (aim for Z' > 0.5)

  • Implement drift correction methods for position effects

• Data normalization and analysis:

  • Develop normalization strategies to account for plate-to-plate variation

  • Implement machine learning algorithms for pattern recognition in image-based screens

  • Validate hits with orthogonal methods and dose-response curves

• Integration with other high-content approaches:

  • Combine UBA7 antibody detection with multiplexed readouts of cellular phenotypes

  • Link UBA7 expression or localization data with functional outcomes

  • Develop data visualization tools to interpret complex datasets

An effective approach might utilize cell-based high-content imaging with UBA7 antibodies combined with ISG15 antibodies to simultaneously assess E1 enzyme levels and substrate conjugation, creating a functional readout of pathway activity suitable for compound screening.